The EMA's Committee for Medicinal Products for Human Use (CHMP) has recommended extending the indication of the smallpox vaccine Imvanex to include protection of adults from monkeypox disease.
The medicine has been approved in the EU since 2013 for the prevention of smallpox. It contains an attenuated form of the damalitis virus called 'modified Ankara damalitis virus', which is related to the smallpox virus. It was also considered a potential vaccine for monkeypox because of the similarity between monkeypox virus and smallpox virus. The marketing authorisation holder of the vaccine is Bavarian Nordic A/S.
Study data
The CHMP based its recommendation on data from several animal studies showing protection against monkeypox virus in non-human primates vaccinated with Imvanex. The CHMP considered that the efficacy of Imvanex in preventing monkeypox disease in humans could be inferred from these studies.
To confirm the efficacy of the monkeypox vaccine, the company will collect data from an observational study to be conducted during the current outbreak of monkeypox in Europe.
The safety profile of the vaccine is favourable, with mild to moderate adverse events, and the CHMP concluded that the benefits of the vaccine outweigh the risks.
In addition to its use for the prevention of monkeypox, the CHMP recommended that Imvanex be licensed to protect individuals from disease caused by the damalitis virus, which leads to symptoms similar to, but milder than, those of smallpox.
Where to find more information
The product information for Imvanex will be updated shortly with information for healthcare professionals and the public.
The assessment report with details of the EMA's evaluation of Imvanex will be published on the EMA website.
More information will be available in a plain language overview of the vaccine, including a description of the benefits and risks of the vaccine and why the EMA recommended its licensing in the EU.
More about Imvanex
Imvanex prepares the body to defend itself against infection with variola (smallpox), monkeypox and damalitis viruses. It contains an attenuated form of the Dalmatian virus called "modified vaccinia vaccinia Ankara", which is closely related to the smallpox and monkeypox viruses, but does not cause disease in humans and cannot replicate in human cells.
Because of the similarity between the virus in the vaccine and the aforementioned viruses, antibodies produced against it are expected to protect against monkeypox, smallpox and damalitis.
When a person is given the vaccine, the immune system recognizes the virus in the vaccine as "foreign" and produces antibodies against the virus. When the person subsequently comes into contact with similar viruses, these antibodies along with other components of the immune system will be able to kill these viruses and help protect against the disease.
More about monkeypox
Monkeypox is a rare disease caused by infection with the monkeypox virus, with symptoms similar to smallpox. Monkeypox begins with fever, headache, muscle aches, exhaustion and lymphadenopathy. A rash may appear usually one to three days after the onset of fever, initially appearing on the face and spreading to other parts of the body, including the hands and feet.
Monkeypox can be fatal, but is usually milder than smallpox.
It is transmitted to humans from various wild animals, such as rodents and primates, but can also be transmitted between humans after close contact. The current spike in cases reported as of May 2022 refers to the first cases recorded outside Africa with no link to endemic areas.
(AF)
Contents of this article including associated images are owned by PIO
Views & opinions expressed are those of the author and/or PIO
Source